News

June 23, 2017

Researchers Test Noninvasive Form of Deep Brain Stimulation on Mice

News

Researchers developed a method for noninvasive deep brain stimulation (DBS) that showed promise as a potential way to stimulate neurons without requiring surgery, a new study says. The method ... Read more

June 22, 2017

Development of Parkinson’s Disease Could Begin in Intestinal Cells, New Study Suggests

News

New research shows that alpha-synuclein is expressed in the enteroendocrine cells (EECs) of the intestine, which are directly connected to nerves that contain α-synuclein, forming a neural circuit between ... Read more

June 21, 2017

NTCELL Shows Promise as Cell Therapy for Parkinson’s Patients

News

Results from a Phase 1/2a clinical trial (NCT01734733) show that treatment with Living Cell Technologies Limited (LCT)’s product NTCELL may be an effective and safe option for patients with ... Read more

June 20, 2017June 20, 2017

Difficulty in Diagnosis Greatly Affects Quality of Life of Parkinson’s Patients, Survey Finds

News

People living with Parkinson’s disease are frustrated with the difficulty in getting an accurate diagnosis, a new Health Union survey found. The “Parkinson’s in America 2017″ survey, conducted online between Jan. 19 ... Read more

June 19, 2017June 19, 2017

Study Reviews Use of Acadia’s Nuplazid as Treatment for Psychosis Linked to Parkinson’s Disease

News

Acadia Pharmaceuticals‘ Nuplazid (pimavanserin) is a reliable treatment to manage hallucinations and delusions associated with Parkinson’s disease psychosis (PDP), but its high cost and restricted access may limit its ... Read more

June 16, 2017June 16, 2017

FDA Reviewing ADS-5102, Possible 1st Treatment for Levodopa-induced Dyskinesia in Parkinson’s

News

Treatment with ADS-5102 (amantadine) significantly decreased levodopa-induced dyskinesia and off-time episodes in patients with Parkinson’s disease at three months, and maintained those benefits for another three months, according to results of a Phase ... Read more

June 15, 2017June 15, 2017

Parkinson’s Vaccine Triggers Solid Immune Response, Phase 1 Clinical Trial Shows

News

AFFiRiS’s new Parkinson’s vaccine, AFFITOPE PD03A, triggered a solid immune response against the alpha-Synuclein (aSyn) protein associated with the disease, according to a Phase 1 clinical trial. Patients also tolerated the therapy well, ... Read more

June 14, 2017June 14, 2017

Muhammad Ali’s Death Had Huge Impact on Parkinson’s Disease Awareness, Survey Shows

News

Almost half of Americans said in a survey that awareness of Parkinson’s disease has increased in the past year due to Muhammad Ali’s long and inspirational fight against the ... Read more

June 13, 2017June 13, 2017

EMA Accepts Phase 3 Trial Design of NeuroDerm’s Experimental Parkinson’s Treatment

News

NeuroDerm received a green light from the European Medicines Agency (EMA) for the main design elements of the amended iNDiGO trial evaluating ND0612 as a treatment for Parkinson’s disease in patients on levodopa with motor ... Read more

June 12, 2017

ND0612H Eliminated Daily Symptoms-recurrence Periods for 42% of Parkinson’s Patients, Trial Shows

News

Forty-two percent of Parkinson’s patients who took ND0612H were able to eliminate periods during the day when their symptoms recurred because their therapy had worn off, according to a Phase ... Read more